Vulvar Cancer

News alerts, weekly reports and conference planners

PD-L1 expression	Vulvar Cancer	PD-L1 expression	Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
NTRK3 fusion	Vulvar Cancer	NTRK3 fusion	Vulvar Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Vulvar Cancer	NTRK2 fusion	Vulvar Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Vulvar Cancer	NTRK1 fusion	Vulvar Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Vulvar Cancer	NTRK3 fusion	Vulvar Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Vulvar Cancer	NTRK2 fusion	Vulvar Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Vulvar Cancer	NTRK1 fusion	Vulvar Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Vulvar Cancer	MSI-H/dMMR	Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
TMB-H	Vulvar Cancer	TMB-H	Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	GC Sensitive: A2 - Guideline GC Sensitive : A2	GC Sensitive: A2 - Guideline GC Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	cisplatin + vinorelbine Sensitive: A2 - Guideline cisplatin + vinorelbine Sensitive : A2	cisplatin + vinorelbine Sensitive: A2 - Guideline cisplatin + vinorelbine Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	CP Sensitive: A2 - Guideline CP Sensitive : A2	CP Sensitive: A2 - Guideline CP Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	FP Sensitive: A2 - Guideline FP Sensitive : A2	FP Sensitive: A2 - Guideline FP Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2
PD-L1 negative	Vulvar Cancer	PD-L1 negative	Vulvar Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PD-L1 overexpression	Vulvar Cancer	PD-L1 overexpression	Vulvar Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4

Vulvar Cancer

Associations(23)

Associations
(23)